LIST OF ONGOING CLINICAL TRIALS WHICH ARE STILL RECRUITING PATIENTS
as of March 2017

TYPE OF CANCER TITLE HOSPITAL PRINCIPAL INVESTIGATOR
Breast A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) – (KEYNOTE-086) SLMC

MMC

Dr. RK Li

Dr. MBE Tamayo

Breast A phase III randomized, double-blind study of PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel for the first-line treatment of patients with HER2-Positive Metastatic Breast Cancer. VMMC Dr. AB Ong-Cornel
Breast A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) SLMC

MMC

Dr. RK Li

Dr. MBE Tamayo

Head and Neck A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma. MMC

SLMC

VMMC

TMC

PSH

Dr. MBE Tamayo

Dr. PB Caguioa

Dr. JP Querol

Dr. EEV Regala

Dr. EMB Villegas

Head and Neck A Randomized, open label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy. SLMC Dr. MG Bello
Head and Neck A Phase II clinical trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma SLMC Dr. PB Caguioa
Head and Neck A phase III randomized, open-label, multi-center, global study of MEDI14736 (Anti-PD-1) Aloneor in Combination with Tremelimumab (CTLA4 inhibitor) versus standard of care in the Treatment of First-Line recurrent or Metastatic Squamous Head and Neck Cancer Patients SLMC Dr. RK Li
Head and Neck A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) monotherapy versus standard chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) SLMC

CDUH

CSMS

DDH

Dr. PB Caguioa

Dr. MNA Uy

Dr. MLA Tiambeng

Dr. FGM Lapus

Liver A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Reximmune-C2 (HSV- Thymidine Kinase-m2 and hGM-CSF) in Refractory Patients with primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver SLMC-QC

SLMC-Global

MMC

TMC

NKTI

Dr. PB Caguioa

Dr. CV Gorospe

Dr. MBE Tamayo

Dr. JP Querol

Dr. NS Juat

Lung AMGEN- 20070782-A Randomized, Double-blind, Placebo-controlled study to evaluate the long term safety and efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in anemic subjects with advanced stage Non-Small Cell Lung Cancer Multi-Cycle Chemotherapy MMC Dr. MBE Tamayo
Lung A Randomized Open-Label Phase III Study of Overall Survival comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer. VMMC

MMC

CDUH

LCP

Dr. CG Galvez

Dr. RT Edusma-Dy

Dr. JY Tan Chun Bing

Dr. GEI Ladrera

Lung A Phase III, Open-Label, Multicenter, Randomized Trial to Establish Safety and Efficacy of an EGFR Cancer Vaccine in Inoperable, Stage IV, Biomarker positive, Wild-type EGFR NSCLC Patients eligible to receive standard treatment and supportive care. MMC

VMCC

Dr. MBE Tamayo

Dr. JP Querol

Lymphoma A Phase 3, Randomized, Double Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patients with CD20-positive. Low Tumor Burden, Follicular Lymphoma USTH Dr. PB Caguioa
Lymphoma A Phase III, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of Copanlisib in combination with Rituximab in patients with relapsed indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) – CHRONOS-3 TMC

SLMC

Dr. BJ Tiangco

Dr. PB Caguioa

Lymphoma A randomized double blind, phase III study comparing biosimilar rituximab (RTXM83) plus chop chemotherapy versus a reference rituximab plus chop (R-CHOP) in patients with Diffuse B-Cell Lymphoma (DBCL) given as first-line VMMC Dr. JP Querol
Pancreas A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer MMC Dr. MBE Tamayo

4 thoughts on “Clinical Trials

  1. Aida Cabrera says:

    Hello, I have a 70+ year old sister in the Philippines who has stage 4 breast cancer. Cancer has spread to the bones. How can she qualify for this clinical trial?

  2. Aida Cabrera says:

    Hello, I have a 70+ year old sister in the Philippines who has stage 4 breast cancer. Cancer has spread to the bones. How can she qualify for this clinical trial?

  3. Vilma Fajardo says:

    I am 45 years old, I was diagnosed with breast cancer stage II in Dec 2016. I took mastectomy and intravenous chemotherapy and Radiotherapy. However after my Radiotherapy two weeks ago the cancer came back with lung metastasis. Please help me to undergo clinical trial for interventional therapy and biological immunotherapy. Please..

  4. Jenalyn Sadac says:

    We are interested to join Clinical Trials for colon cancer. Please assist my father for any trials for colon cancer. thank you. We will be waiting for your reply.

Leave a Reply

Your email address will not be published.